In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Immune Response licenses Hybridon's 2nd-generation CpG DNA adjuvant
Electroporation gives HIV vaccine development a major boost
Immune Response Corporation not to proceed with HIV study
The Immune Response Corporation announces payment from Agouron Pharmaceuticals
ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
Immune Response initiates phase I trial of brain tumour vaccine
Immune Response receives two U.S. patents
ImmunoVaccine Technologies to Develop Pseudomonas Vaccine from Yokohama City University